UroGen Pharma has opened another front in its attack on bladder cancer, paying IconOVir Bio $4 million in stock for an ...

There are around 2,800 new cases of malignant glioma ... participated in the clinical trial programme. It is the first oncolytic virus therapy to be launched anywhere in the world for brain ...

Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...

It's not the first therapy in the oncolytic virus class to be approved around the world, as that accolade went to Amgen's Imlygic (talimogene laherparepvec), which was cleared by the FDA for the ...

Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...

Imugene's trial programs could result in the first 'off the shelf' Car-T therapy that uses healthy donors' cells.

Versa, the global leader in Universal Secure Access Service Edge (SASE), today announced the general commercial availability of Versa Sovereign SASEtm, uniquely allowing enterprises, governments, and ...

In this video, Annick Desjardins, MD, professor of neurosurgery, professor of neurology and member of the Duke Cancer Institute, discusses what she is most looking forward to in the future of brain ...

CAR T-Cell therapy market growth is propelled by revolutionary results in treating certain blood cancers.New Delhi, Feb. 07, 2025 (GLOBE NEWSWIRE) -- The global CAR T-cell therapy market valuation is ...

Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the company ...

Pelareorep's mechanism of action as an oncolytic virus immunotherapy offers a novel ... which include discussions around partnerships for pelareorep. This article was generated with the support ...